Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MIRA Pharmaceuticals, Inc. Common Stock (MIRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: MIRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -61.85% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.82M USD | Price to earnings Ratio - | 1Y Target Price 17.75 |
Price to earnings Ratio - | 1Y Target Price 17.75 | ||
Volume (30-day avg) 318500 | Beta - | 52 Weeks Range 0.51 - 5.01 | Updated Date 04/2/2025 |
52 Weeks Range 0.51 - 5.01 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -81.27% | Return on Equity (TTM) -192.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12288191 | Price to Sales(TTM) - |
Enterprise Value 12288191 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.45 | Shares Outstanding 16560900 | Shares Floating 10569301 |
Shares Outstanding 16560900 | Shares Floating 10569301 | ||
Percent Insiders 23.68 | Percent Institutions 6.61 |
Analyst Ratings
Rating 5 | Target Price 12.08 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MIRA Pharmaceuticals, Inc. Common Stock
Company Overview
History and Background
MIRA Pharmaceuticals, Inc. is a pre-clinical stage pharmaceutical company focused on developing and commercializing a new generation of drugs to address unmet needs in the treatment of neurologic and neuropsychiatric disorders. Founded to develop novel therapies for conditions like anxiety and PTSD, the company is pursuing synthetic cannabinoid analogs.
Core Business Areas
- Drug Development: Focuses on developing and commercializing proprietary drug candidates targeting neurologic and neuropsychiatric disorders.
- Pre-clinical Research: Conducting pre-clinical studies to evaluate the safety and efficacy of its drug candidates.
- Intellectual Property: Building a portfolio of intellectual property related to its drug candidates and technologies.
Leadership and Structure
The leadership team comprises experienced pharmaceutical executives and scientific advisors. The organizational structure is typical of a pre-clinical stage biotech company, with emphasis on research and development.
Top Products and Market Share
Key Offerings
- Ketamir-2: MIRA's lead product candidate, Ketamir-2, is a synthetic cannabinoid analog being developed for the treatment of anxiety and PTSD. It is currently in pre-clinical development. Market share is N/A as it is not yet commercialized. Competitors in the anxiety and PTSD treatment market include companies like Pfizer (Zoloft, US stock symbol: PFE), Eli Lilly (Prozac, US stock symbol: LLY), and Johnson & Johnson (Spravato, US stock symbol: JNJ).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. There's a growing demand for novel treatments for neurological and neuropsychiatric disorders.
Positioning
MIRA Pharmaceuticals is positioning itself as an innovator in the development of synthetic cannabinoid analogs for treating anxiety and PTSD. Its competitive advantage lies in its proprietary drug candidates and intellectual property.
Total Addressable Market (TAM)
The global market for anxiety and PTSD treatments is estimated to be worth billions of dollars. MIRA is positioned to capture a portion of this TAM with its novel therapies, though its current share is effectively zero given its pre-clinical stage. The total addressable market for PTSD is roughly 8 billion USD with the total addressable market for anxiety being roughly 20 billion USD.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Strong intellectual property portfolio (patent pending)
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Pre-clinical stage, high risk of failure
- Limited financial resources
- Reliance on successful clinical trials
- Lack of revenue generation
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Government grants and funding opportunities
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
- Changes in legislation regarding cannabinoids
Competitors and Market Share
Key Competitors
- PFE
- LLY
- JNJ
Competitive Landscape
MIRA Pharmaceuticals faces intense competition from established pharmaceutical companies. Its advantage lies in its novel drug candidates, but it needs to successfully navigate the regulatory and clinical trial process to gain market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to its pre-clinical stage. Growth is measured by progress in drug development and fundraising activities.
Future Projections: Future growth projections are based on analyst estimates of the potential market for its drug candidates and the likelihood of successful clinical trials. Dependent on FDA approvals.
Recent Initiatives: Recent initiatives include advancing Ketamir-2 into clinical trials and expanding its intellectual property portfolio.
Summary
MIRA Pharmaceuticals is a high-risk, high-reward pre-clinical stage company focused on developing novel therapies for neurologic and neuropsychiatric disorders. Its strengths lie in its innovative drug candidates and experienced management team. However, it faces significant challenges related to clinical trial success, regulatory hurdles, and competition from larger pharmaceutical companies. The company's future hinges on the successful development and commercialization of its lead product candidates.
Similar Companies
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in pre-clinical stage pharmaceutical companies involves significant risk of loss.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MIRA Pharmaceuticals, Inc. Common Stock
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2023-08-03 | CEO & Chairman Mr. Erez Aminov | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees - | Website https://mirapharmaceuticals.com |
Full time employees - | Website https://mirapharmaceuticals.com | ||
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.